Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CONMED Corporation is a publicly traded medical technology company that develops, manufactures, and sells surgical devices and equipment used primarily in minimally invasive and general surgical procedures. The company operates within the medical devices and healthcare technology industry, with a focus on improving clinical outcomes, surgical efficiency, and patient safety. Its products are used across a wide range of surgical specialties, including orthopedics, general surgery, gastroenterology, pulmonology, and gynecology.
The company’s primary revenue drivers include surgical instrumentation, endomechanical devices, visualization systems, and single-use and reusable medical supplies. CONMED serves hospitals, ambulatory surgery centers, and outpatient clinics, positioning itself as a comprehensive provider of procedure-enabling technologies. Founded in 1970 and headquartered in the United States, CONMED has evolved from a domestic surgical supply manufacturer into a globally active medical technology company through organic development and targeted acquisitions.
Business Operations
CONMED operates as a single reportable business segment, generating revenue through the sale of medical devices, capital equipment, and related disposable products. Its core product categories include orthopedic surgery solutions, general surgery devices, endoscopic technologies, electrosurgical systems, and advanced energy and visualization platforms. These offerings are designed to integrate into surgical workflows, creating recurring revenue through consumables tied to capital equipment installations.
The company conducts operations in both domestic and international markets, with manufacturing, sourcing, and distribution capabilities supporting global sales. CONMED controls proprietary technologies related to minimally invasive surgery and tissue management and sells products under well-established brands such as Linvatec and Utica Enterprises. Distribution is managed through a combination of direct sales forces and independent distributors, depending on the region.
Strategic Position & Investments
CONMED’s strategic direction emphasizes consistent organic growth, margin expansion, and portfolio optimization within higher-growth surgical categories. The company invests in product innovation focused on minimally invasive and outpatient procedures, aligning with broader healthcare trends toward cost efficiency and reduced patient recovery times. Research and development efforts are directed toward advanced surgical visualization, single-use devices, and integrated surgical systems.
Historically, CONMED has pursued selective acquisitions to strengthen its product portfolio and expand market access. A notable acquisition includes Aspen Surgical, which broadened the company’s presence in disposable surgical products. The company continues to evaluate investments in adjacent technologies and complementary product lines, though details on future transactions are not always disclosed publicly. Where acquisition or investment timelines are not confirmed, data is inconclusive based on available public sources.
Geographic Footprint
CONMED is headquartered in the United States and maintains a significant presence across North America, which represents its largest revenue-generating region. The company also operates extensively in Europe, Asia-Pacific, and Latin America, supported by regional sales offices, distribution partners, and logistics infrastructure.
International operations contribute a meaningful portion of total revenue and are central to the company’s long-term growth strategy. CONMED’s products are sold in over 100 countries, with expanding exposure to emerging healthcare markets. Its global footprint allows the company to diversify revenue streams while responding to region-specific surgical practices and regulatory environments.
Leadership & Governance
CONMED is led by an experienced executive team with backgrounds in medical technology, operations, and corporate finance. The leadership team emphasizes disciplined capital allocation, customer-focused innovation, and operational excellence as core elements of the company’s strategic vision. Governance practices align with public company standards and regulatory requirements applicable to U.S.-listed issuers.
Key executives include:
- Curt R. Hartman – President and Chief Executive Officer
- Todd W. Garner – Chief Financial Officer
- Patrick J. Beyer – Chief Operating Officer
Information regarding founders and certain historical leadership roles varies across public disclosures; where discrepancies exist, data is inconclusive based on available public sources.